Results from a Randomized Phase 1-2 Trial Evaluating the Safety and Antitumor Activity of Anti-PD-1 (MEDI0680)  Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear ...

Results from a Randomized Phase 1-2 Trial Evaluating the Safety and Antitumor Activity of Anti-PD-1 (MEDI0680) Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear ...

kidneycancer

3 months
18 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Martin H. Voss1, Arun Azad2, Aaron R. Hansen3, Jhanelle E. Gray4, Sarah J. Welsh5, Xuyang Song6, Ikbel Achour6, Heping Hu6, Lisa Lewis6, Farzana L. Walcott6, Sjoukje F. Oosting7

1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Monash Health, Melbourne, Australia; 3Princess Margaret Cancer Centre, Toronto, Canada; 4Moffitt Cancer Center, Tampa, FL, USA; 5Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 6AstraZeneca, Gaithersburg, MD, USA; 7University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Results from a Randomized Phase 1-2 Trial Evaluating the Safety and Antitumor Activity of Anti-PD-1 (MEDI0680) Anti-PD-L1 (Durvalumab) vs Anti-PD-1 (Nivolumab) Alone in Metastatic Clear Cell Renal Cell Carcinoma at the 18th International Kidney Cancer Symposium 2019, Miami, FL.



Up Next Autoplay